Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: PR Newswire
Highly experienced Chief Financial Officer set to drive corporate and strategic goals of Resolution. Accomplished Chief Business Officer will drive business development and partnering deals. Appointments follow the announcement of the first patient dosed and safety cleared in its Phase I/II EMERALD study.EDINBURGH, Scotland and LONDON, Sept. 10, 2025 /PRNewswire/ -- Resolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces the appointment of Lucy Singah as Chief Financial Officer (CFO) and Daniel Kennedy as Chief Business Officer (CBO).Dr. Amir Hefni, Chief Executive Officer of Resolution Therapeutics, said: "We are delighted to welcome Lucy and Dan to our leadership team at this exciting time in the Company's journey, having recently announced the successful dosing of the first patient with RTX001. I look forward to working w
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore (IMCR) Q2 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- The Galien Foundation Announces 2025 Prix Galien Bridges Awards Nominees for "Best Bridge-Builder Institution," "Best Biomedical Product," "Best Medical Technology/AI Advances in Human Health," "Best Product for Rare/Orphan Diseases," and "Best Public SecPR Newswire
- Immunocore (NASDAQ:IMCR) had its price target raised by analysts at Morgan Stanley from $34.00 to $36.00. They now have an "equal weight" rating on the stock.MarketBeat
- Immunocore to present at upcoming investor conferencesGlobeNewswire
- Immunocore Holdings plc (NASDAQ:IMCR) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 11/6/25 - Beat
IMCR
Sec Filings
- 12/1/25 - Form 4
- 11/28/25 - Form 8-K
- 11/26/25 - Form 4
- IMCR's page on the SEC website